Sylvie Claeysen
  • E-mail :[email]
  • Phone : +33 4 34 35 92 15
  • Location : Montpellier, France
Last update 2016-02-23 18:27:40.293

Sylvie Claeysen PhD Molecular Neuroscience & Pharmacology

Course and current status

  • 2006-2016: Permanent researcher at INSERM (CR1 level) – Institute of Functional Genomics (IGF), CNRS UMR5203, INSERM U661, Montpellier University – Montpellier – FRANCE – Head: Dr. Jean-Philippe Pin
  • 2002-2006: Permanent researcher at INSERM (CR2 level) – Laboratory of Functional Genomics (LGF), CNRS UPR 2580 – Montpellier – FRANCE – Head: Pr. Joël Bockaert 
  • 2000-2002: Post-doctoral training – Institute of Interdisciplinary Research  in Human and Molecular Biology (IRIBHM) – Bruxelles  – BELGIUM – Head: Pr. Gilbert Vassart
  • 1995-1999: PhD obtained from University of Montpellier II – Achieved in CNRS INSERM Center of Pharmacology and Endocrinology (CCIPE)  – CNRS UPR 9023 – Montpellier – FRANCE – Advisor: Aline Dumuis – Head: Pr. Joël Bockaert

Scientific summary

Holder of a permanent position at INSERM and of an accreditation to supervise Ph.D. students, I develop programs in Molecular Pharmacology and Neurosciences on serotoninergic 5-HT4 receptor (activation mechanisms, dimerization, function…) in the team "Neuroproteomics and Signaling of Neurological and Psychiatric Disorders" headed by Philippe MARIN. In association with an international network of scientists engineering RASSL and DREAD receptors (Receptors Activated Solely by Synthetic Ligands and not by their endogenous ligands), we develop interesting tools that present promising applications in Physiology and in Gene Therapy.

Driving the research project concerning 5-HT4 receptor in the team, I initiate novel research strategies, based on a deep knowledge, accumulated during the past years on molecular and cellular mechanisms induced by this receptor. In this context, we carry out a project of which ultimate aim is to validate a new therapeutic target in the Alzheimer’s disease context. It relies on an original approach aimed at unbalancing APP maturation towards a non-amyloidogenic protective pathway, by controlling APP traffic and α-secretase cleavage. This view of α‑secretase control by a GPCR is particularly innovative and promising. In a collaborative effort with chemists and behaviour specialists, I also contribute to the conception and characterisation of new therapeutic agents that activate the non-amyloidogenic protective pathway for prevention of Alzheimer's disease.

Funding :

  • 2016-2018: Ligue Européenne Contre la Maladie d'Alzheimer, L.E.C.M.A., PI
  • 2015-2017: Fondation Plan Alzheimer
  • 2015-2017: Fédération pour la Recherche sur le Cerveau, FRC
  • 2013-2017: French National Research Agency, ANR
  • 2012-2014: Ligue Européenne Contre la Maladie d'Alzheimer, L.E.C.M.A., PI
  • 2011-2015: Région Languedoc-Roussillon, PI
  • 2011-2013: Soroptimist International (French Union), PI
  • 2011-2013: France Alzheimer association, PI
  • 2006-2010: French National Research Agency, ANR
  • 2005-2006: Collaborative contract with Pfizer
  • 2004-2006: Fondation de France, PI

Awards :

  • 2013: Junior Faculty Award – AD/PD™ 2013 - The Alzheimer's & Parkinson's Conference
  • 2012: "Chercheuse d'avenir" of the Languedoc Roussillon Region
  • 2011: Soroptimist International (French Union) medal
  • 2010: 2010 Research Prize of the France Alzheimer association
  • 1997: Roche Bioscience Prize Advances in Serotonin Receptor Research, San Francisco, USA.



Image d’exemple